ライフサイエンスコーパス: cellular immunotherapy

1 ed to obtain sufficient numbers of cells for cellular immunotherapy.

2 detection of T cell populations relevant to cellular immunotherapy.

3 a novel approach for vaccine development and cellular immunotherapy.

4 in NPC renders it an appealing candidate for cellular immunotherapy.

5 d underscores their potential application in cellular immunotherapy.

6 h in animal models and in clinical trials of cellular immunotherapy.

7 xpansion of these cells for potential use in cellular immunotherapy.

8 imerism as a potential platform for adoptive cellular immunotherapy.

9 in the development of new forms of adoptive cellular immunotherapy.

10 ymopoiesis, and the use of adjuvant-targeted cellular immunotherapies.

11 ress, which influences delivery of drugs and cellular immunotherapies.

12 Adoptive cellular immunotherapy (ACT) is a potentially curative t

13 cancer vaccine trials, but also for adoptive cellular immunotherapy after ex vivo expansion.

14 ces in laboratory and clinical procedures in cellular immunotherapy, along with the development of po

15 e this metabolic quiescence and thus augment cellular immunotherapy-based cancer therapy.

16 lantation and after transplantation adoptive cellular immunotherapy but may be complicated by a high

17 This cellular immunotherapy can modulate beta chemokine produ

18 understanding of ongoing cancer vaccine and cellular immunotherapy clinical trials.

19 Tumor vaccines and cellular immunotherapies could synergize with checkpoint

20 trategies in cytokine therapy, vaccines, and cellular immunotherapy, each of which might become viabl

21 Tumor vaccines and cellular immunotherapies enhanced OS and PFS in NSCLC.

22 isease onset, suggesting a novel approach to cellular immunotherapy for autoimmunity.

23 uggest a potential novel approach to augment cellular immunotherapy for cancer.

24 HSCT) has evolved into an effective adoptive cellular immunotherapy for the treatment of a number of

25 be critical in developing effective adoptive cellular immunotherapy for viral infections and cancer.

26 nce EBV-specific T cells could prevent PTLD, cellular immunotherapy has been a promising treatment op

27 Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy i

28 onments, to generate more effective adoptive cellular immunotherapies in cancer, and to direct T cell

29 a strong rationale for the investigation of cellular immunotherapy in B-cell NHL.

30 produce tumor-specific T cells for adoptive cellular immunotherapy in melanoma patients.

31 sessed the efficacy of tumor vaccination and cellular immunotherapy in NSCLC.

32 mediated cytotoxicity in vitro, and adoptive cellular immunotherapy in vivo.

33 This cellular immunotherapy is a short-term available and bro

34 Allogeneic cellular immunotherapy is effective even with the use of

35 Autologous cellular immunotherapy is hindered by the inability to b

36 ssing the potential of CD4+ CD25+ Tregs as a cellular immunotherapy is their hypoproliferative phenot

37 Cellular immunotherapy may provide a strategy to overcom

38 bes future avenues for their exploitation in cellular immunotherapy of malignant blood disorders.

39 mized controlled trials (RCTs) investigating cellular immunotherapy or vaccines in NSCLC.

40 This form of cellular immunotherapy presents a unique opportunity to

41 ipulation of OX40 may be useful in improving cellular immunotherapy regimes for treatment of persiste

42 l rationale to target them as a personalized cellular immunotherapy strategy, an especially appealing

43 ), this tumor is an attractive candidate for cellular immunotherapy targeted against tumor-associated

44 ests this tumor can be highly susceptible to cellular immunotherapy targeted to tumor associated anti

45 enrolled onto a clinical trial of autologous cellular immunotherapy targeting human epidermal growth

46 We have developed a cellular immunotherapy that uses chimeric receptors to s

47 Despite the major improvements in cellular immunotherapy, the immunogenicity of virus-spec

48 ress in the application of novel humoral and cellular immunotherapies to children and adolescents wit

49 ts, these cells have potential to be used as cellular immunotherapy to control transplant arterioscle

50 Cellular immunotherapy to prevent CMV disease is less to

51 uld potentially serve as target antigens for cellular immunotherapy to promote GVL activity after all

52 y and gammadelta T cell-based drug resistant cellular immunotherapy to treat GBM.

53 Adoptive cellular immunotherapy treats metastatic cancer by infus

54 were performed in anticipation of its use in cellular immunotherapy trials for primary malignant brai

55 novel nontoxic and efficacious paradigm for cellular immunotherapy trials in human primary malignant

56 mmunotherapy using monoclonal antibodies and cellular immunotherapy using hematopoietic cell transpla

57 Adoptive cellular immunotherapy utilizing tumor-reactive T cells

58 Cellular immunotherapy was found to be more effective th

59 d mixed chimerism as a platform for adoptive cellular immunotherapy was reliably induced.

60 Lapuleucel-T (APC8024), an autologous active cellular immunotherapy, was prepared from peripheral-blo

61 Autologous active cellular immunotherapy with lapuleucel-T was feasible, s

62 allogeneic T cells thus represent a form of cellular immunotherapy with time-limited biologic activi